This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways
Breast Cancer Research Open Access 21 July 2023
-
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
Oncogenesis Open Access 26 May 2023
-
The effects of MYC on tumor immunity and immunotherapy
Cell Death Discovery Open Access 25 March 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–2390.
Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015; 27: 516–532.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284.
Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11–23.
Sharma P, Allison JP . The future of immune checkpoint therapy. Science 2015; 348: 56–61.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.
Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 2016; 127: 3026–3034.
Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 2016; 34: 2690–2697.
Chen J, Jiang CC, Jin L, Zhang XD . Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 2016; 27: 409–416.
Kwiecinska A, Tsesmetzis N, Ghaderi M, Kis L, Saft L, Rassidakis GZ . CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma. Br J Haematol 2016; e-pub ahead of print 23 November 2016; doi: 10.1111/bjh.14432.
Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003; 9 (10 Pt 1): 3692–3699.
Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105: 20852–20857.
Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A . Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol 2016; 54: 17–24.
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–3473.
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016; 352: 227–231.
Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 2015; 125: 124–132.
Acknowledgements
GZR is a recipient of a Radiumhemmets Forskningsfonder grant (Sweden). NT is a recipient of a Hellenic Association for Molecular Cancer Research (HAMCR) scholarship.
Author contributions
VA, NT, DC, LK, ED and TP performed research, analyzed the data and contributed to the writing of the paper. LJM, KY and VL contributed vital reagents or clinical samples and also contributed to the writing of the paper. GZR conceived the hypothesis, designed research, analyzed the data and wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Atsaves, V., Tsesmetzis, N., Chioureas, D. et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31, 1633–1637 (2017). https://doi.org/10.1038/leu.2017.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.103
This article is cited by
-
Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways
Breast Cancer Research (2023)
-
The effects of MYC on tumor immunity and immunotherapy
Cell Death Discovery (2023)
-
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
Oncogenesis (2023)
-
PAQR5 inhibits the growth and metastasis of clear cell renal cell carcinoma by suppressing the JAK/STAT3 signaling pathway
Cellular Oncology (2023)
-
Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Cell Communication and Signaling (2022)